While many HIV prevention interventions have traditionally been delivered face-to-face, a study from Columbia University School of Nursing suggests that digital outreach efforts delivered via text messages, interactive games, chat rooms, and social networks may be an effective way to reach at-risk younger men who have sex with men.
June 27 is National HIV Testing Day and Loyola University Health System will celebrate as they do every day – by offering free HIV testing to patients in the emergency department and at select immediate care centers.
“We currently offer HIV testing at our Maywood emergency department and also at Loyola Burr Ridge immediate care” says Beatrice Probst, MD, medical director of the immediate care centers at Loyola University Health System. Expanding testing to the Loyola Park Ridge immediate care center starts Friday, June 27, which is National HIV Testing Day.
“In 2014 alone, Loyola’s testing program identified three new HIV-infected patients. One was acute HIV, meaning the individual had recently acquired the infection and is at the most infectious stage,” says Probst
A new study of NYC deaths of people with HIV/AIDS shows the portion of AIDS deaths increased significantly in the Bronx and Brooklyn while tumbling in Manhattan from 2005 to 2012. This major change in death patterns occurred after the Bloomberg Administration "reallocated" almost 60% of
federal AIDS funny for community-based outreach and support to Manhattan while de-funding some 60 local support programs in the Bronx and Brooklyn.
Family and cultural pressures to conform to prescribed masculine behaviors create social isolation and distress that may drive young gay black men to seek approval and acceptance through perilous sexual behaviors, according to research led by investigators at the Johns Hopkins Children’s Center. This dangerous “compensatory” mechanism, the researchers say, may contribute to the disproportionately high HIV infection rate seen in this population.
Researchers at the University of California, San Diego School of Medicine have mapped the transmission network of human immunodeficiency virus (HIV) in San Diego. The mapping of HIV infections, which used genetic sequencing, allowed researchers to predictively model the likelihood of new HIV transmissions and identify persons at greatest risk for transmitting the virus.
Researchers following almost 450 children enrolled in the Pediatric HIV/AIDS Cohort Study, one of the largest studies of HIV-positive children in the United States, found that 74 percent had developed resistance to at least one form of drug treatment.
HIV may now be a chronic, manageable disease for most patients in the United States, but mothers and children in sub-Saharan Africa are still suffering. One UAB School of Public Health researcher hopes to improve their situation.
University of Utah researchers devised a way to watch newly forming AIDS virus particles “budding” from human cells without interfering with the process. The method shows a protein named ALIX gets involved during the final stages of virus replication, not earlier, as was believed previously.
A vaccine or other therapy directed at a single site on a surface protein of HIV could in principle neutralize nearly all strains of the virus—thanks to the diversity of targets the site presents to the human immune system.
Even if treated, hypertension and high cholesterol are increasingly common for people with human immunodeficiency virus (HIV), according to a new study from researchers at Mount Sinai St. Luke’s and Mount Sinai Roosevelt hospitals in New York and the University of California, Davis.
Penn medicine researchers find much stronger association between alcohol use and advanced liver fibrosis in co-infected patients compared to uninfected
Johns Hopkins biochemists have figured out what is needed to activate and sustain the virus-fighting activity of an enzyme found in CD4+ T cells, the human immune cells infected by HIV. The discovery could launch a more effective strategy for preventing the spread of HIV.
Researchers have discovered a new class of proteins capable of blocking the HIV virus from penetrating T-cells, raising hope that the proteins could be adapted for use in gels or sexual lubricants to provide a potent barrier against HIV infection.
A team led by scientists at The Scripps Research Institute (TSRI) working with the International AIDS Vaccine Initiative (IAVI) has discovered a new vulnerable site on the HIV virus.
Study finds that communities in Africa and Thailand that worked together on HIV-prevention efforts saw not only a rise in HIV screening but a drop in new infections, demonstrating that programs such as this can encourage community-wide testing and help reduce HIV transmission.
Nearly half of people living with HIV experience cognitive deficits that may impact instrumental activities of daily living, including driving, according to University of Alabama at Birmingham School of Nursing research published in the March issue of the Journal of the Association of Nurses in AIDS Care.
Men with long-term HIV infections are at higher risk than uninfected men of developing plaque in their coronary arteries, regardless of their other risk factors for coronary artery disease, according to results of a study led by Johns Hopkins researchers. A report on the research appears in the April 1 issue of Annals of Internal Medicine.
Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with University of Adelaide researchers applying for a patent based on groundbreaking new research.
Scientists at Johns Hopkins report that compounds they hoped would “wake
up” dormant reservoirs of HIV inside immune system T cells — a strategy
designed to reverse latency and make the cells vulnerable to destruction
— have failed to do so in laboratory tests of such white blood cells taken directly from patients infected with HIV.
It’s an unfortunate reality for many in low-income racial and ethnic minority communities: Unemployment is disproportionately high, crime is an ever-present problem, access to affordable health care can be nonexistent, and the struggle to pay rent and keep food on the table is a daily challenge. For these communities, the last thing on anyone’s mind is AIDS.
A multi-national research team led by Duke Medicine scientists has identified a subclass of antibodies associated with an effective immune response to an HIV vaccine.
A new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the risk of hepatitis C-associated serious liver disease persists in HIV patients otherwise benefitting from antiretroviral therapy (ART) to treat HIV.
Little research has been done to help explain how HIV epidemics and programs in one population affect others and how to reduce the risks of transmission. Now, a recent study sheds light on the pathways connecting HIV epidemics in different populations.
One person’s unique ability to fight HIV has provided key insights into an immune response that researchers now hope to trigger with a vaccine, according to findings reported by a team that includes Duke Medicine scientists.
A Phase I trial conducted at UAB was designed to evaluate the safety, acceptability and drug absorption qualities of an intravaginal ring containing two anti-HIV medications when worn by women for 28 days.
University of Pennsylvania researchers have successfully genetically engineered the immune cells of 12 HIV positive patients to resist infection, and decreased the viral loads of some patients taken off antiretroviral drug therapy (ADT) entirely—including one patient whose levels became undetectable. The study, appearing today in the New England Journal of Medicine, is the first published report of any gene editing approach in humans.
According to Pierre-Marie David of the University of Montreal’s Faculty of Pharmacy, stock-outs of antiretroviral (ARV) drugs in recent years in the Central African Republic have had a dramatic impact on the health of HIV-infected people.
Researchers find evidence that photosensitizing a virus's membrane covering can inhibit its ability to enter cells and potentially lead to the development of stronger, cheaper medications to fight a host of tough viruses.
Real-time social media like Twitter could be used to track HIV incidence and drug-related behaviors with the aim of detecting and potentially preventing outbreaks
Michael Saag, M.D., has been seeing HIV patients from the beginning, and uses that journey to illustrate what he believes needs to change with health care.
Dallas Buyers Club captures the despair and frustration of the AIDS crisis but misses the mark on profits. In a video interview, Dr. Mike Saag, past pres. of the HIV Medical Assn & director of the Center for AIDS Research, gives a non-Hollywood review of the movie.
For the millions of people living with HIV/AIDS, antiretroviral drugs can be a lifeline, slowing the progress of viral infection. Unfortunately, studies have shown that these benefits can be short-lived: therapy can lead to mutations in the HIV genetic code, which can make the virus resistant to drugs. However, researchers at the 58th Annual Biophysical Society Meeting will present new insight into how the therapy functions and how therapy-induced point mutations actually confer drug resistance.
People receiving mental health care are up to four times more likely to be infected with HIV than the general population, according to a new study published Feb. 13 in the American Journal of Public Health from researchers at Penn Medicine and other institutions who tested over 1,000 patients in care in Philadelphia and Baltimore. Of that group, several new HIV cases were detected, suggesting that not all patients are getting tested in mental health care settings, despite recommendations to do so from the CDC and the Institute of Medicine.
Scientists at The Scripps Research Institute have invented a new method for designing artificial proteins and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality.
A new study published in the Journal of Biological Chemistry by George Washington University researcher Michael Bukrinsky, M.D., Ph.D., shows similarities in the pathogenesis of prion disease — misfolded proteins that can lead to neurological diseases — and the HIV virus.
Nearly half of HIV-infected teenagers and young adults forego timely treatment, delaying care until their disease has advanced, which puts them at risk for dangerous infections and long-term complications, according to a study led by the Johns Hopkins Children’s Center.
Scientists have identified a way some viruses protect themselves from the immune system’s efforts to stop infections, a finding that may make new approaches to treating viral infections possible.
Researchers, led by Prof. John B. Jemmott, III, Annenberg School for Communication and the Perelman School of Medicine; and Loretta Sweet Jemmott, Director of the Center for Health Equity Research at Penn Nursing,* developed an intervention involving nearly 1,200 individuals, who participated in customized and proactive education programs on condom usage and the importance of discussing safe sex in their relationships. The results of their study are being reported this week in the American Journal of Public Health (Volume 104, Issue 2).
Seattle BioMed researchers identified two HIV-1 Envelope immunogens that elicit broadly neutralizing antibodies when introduced as a vaccine. The study was published online in PLOS One.
Decade-long study reported by an international team that includes University of Delaware researchers shows that stem-cell memory T-cells (Tscm) play an increasingly significant role in sustaining HIV infection in patients that have remained on therapy.
Wistar’s Dr. Luis Montaner leads a Philadelphia-based clinical trial – the largest of its kind to date – focused on depleting the viral reservoir in HIV patients and potentially leading toward a cure for the disease.
Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV – a combination therapy that targets HIV-infected cells that standard therapies cannot kill.
Researchers studied the impact of comorbidity on two critical health-care-quality indicators and found that secondary conditions and diseases significantly affect hospital length of stay and total charges for HIV patients.
• HIV infection occurred in 68% of the HIV-positive transplant recipients’ new kidneys even in the absence of any detectable HIV in their blood.
• A new urine test can detect these infections and lead to better diagnosis and treatment
Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling it could help restore the cells’ ability to combat the virus that causes AIDS.
More than 22,000 inmates entering North Carolina prisons in 2008 and 2009 were tested for HIV, but only 20 new cases of HIV were found, in a study led by Dr. David Wohl of the University of North Carolina School of Medicine.
Sharon Nachman, MD, a pediatric HIV specialist at Stony Brook Children’s Hospital, is a co-author of new NIH-issued guidelines for the prevention, treatment and management of opportunistic infections in HIV-infected children.